Neumonía intersticial no específica (NINE) secundaria al tratamiento con imatinib. A propósito de un caso y revisión de la literatura

  1. Azofra-Macarrón, Carlos 1
  2. Robaina-Cabrera, Dimas Manuel 1
  3. Anta-Fernández, Manuela 2
  4. González-Pascual, Andrea 2
  5. Miguel-Sánchez, Carlos de 3
  1. 1 Servicio de Medicina Familiar y Comunitaria, Hospital Sierrallana, Torrelavega (Cantabria), España
  2. 2 Servicio de Medicina Interna, Hospital Sierrallana, Torrelavega (Cantabria), España
  3. 3 Servicio de Hematología, Hospital Sierrallana, Torrelavega (Cantabria), España
Show affiliations +
Journal:
Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

ISSN: 2530-0792

Year of publication: 2017

Issue Title: Spanish Journal of Case Records in Internal Medicine

Volume: 2

Issue: 3

Pages: 128-130

Type: Article

DOI: 10.32818/RECCMI.A2N3A9 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

Sustainable development goals

Abstract

Imatinib is a powerful and selective inhibitor of the protein tirosine kinase BCR-ABL with clinical significant efficacy for the treatment of chronic myeloid leukemia (CML). Pulmonary toxicity induced by Imatinib has got a wide range of presentations and symptoms, being the interstitial neumonitis an exceptional example regarding literature. In this case, patients normally show a non specific interstitial neumonitis and evolution is generally good after treatment withdrawal and therapy with esteroids. We present the case of a 74-years-old male with interstitial neumonitis caused by Imatinib prescribed for CML in chronic phase.

Bibliographic References

  • O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11): 994-1004. doi: https://doi.org/10.1056/NEJMoa022457.
  • Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28; 346(9): 645-652. Erratum in: N Engl J Med. 2002 Jun 13; 346(24): 1923. doi: https://doi.org/10.1056/NEJMoa011573.
  • Go SW, Kim BK, Lee SH, Kim TJ, Huh JY, Lee JM, et al. Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis. Tuberc Respir Dis. 2013 Dec; 75(6): 256-259. doi: https://doi.org/10.4046/trd.2013.75.6.256.
  • Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006 Jun; 20(6): 1162-1164. doi: https://doi.org/10.1038/sj.leu.2404207.
  • Eşkazan AE, Salihoğlu A, Erturan S, Soysal T. Interstitial pneumonitis in a patient with chronic myeloid leukemia. Turk J Haematol. 2013 Dec; 30(4): 435-436. doi: https://doi.org/10.4274/Tjh.2012.0115. Epub 2013 Dec 5.
  • Lee NR, Jang JW, Kim HS, Yhim HY. Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection. Korean J Intern Med. 2015 Jul; 30(4): 550-553. doi: https://doi.org/10.3904/kjim.2015.30.4.550.
  • Sugaya A, Ishiguro S, Mitsuhashi S, Abe M, Hashimoto I, Kaburagi T, et al. Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases. Mol Clin Oncol. 2017 Feb; 6(2): 229-232. doi: https://doi.org/10.3892/mco.2016.1113.
  • Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006 Mar; 17(3): 372-379. Epub 2005 Nov 16. Review. doi: https://doi.org/10.1093/annonc/mdj057.
Data source: Dialnet